Neoadjuvant chemo underused in patients with advanced gastric
Neoadjuvant chemotherapy (NAC) remains underused in patients with advanced gastric cancer, despite evidence that it does not worsen perioperative outcomes, U.S. researchers report.
Neoadjuvant chemotherapy (NAC) remains underused in patients with advanced gastric cancer, despite evidence that it does not worsen perioperative outcomes, U.S. researchers report.
For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE